Poly Medicure Ltd Q2 FY26: ₹444 Cr Sales, ₹92 Cr PAT, Global Expansion Spree, and an R&D Frenzy in Medical Plastic Royalty
1. At a Glance
Welcome to the world of Polymed, the silent doctor in your IV line and the overachieving cousin every FMCG company wishes it had. The stock is currently trading at ₹1,894 with a market cap of ₹19,195 crore, a P/E of 53, and a ROCE of 20%. That’s right — it’s expensive, but like all good medical bills, it somehow feels justified.
In Q2 FY26, the company delivered ₹444 crore in revenue, growing 5.68% YoY, while PAT stood at ₹92 crore, up 5.02% YoY. The operating margin stayed a healthy 26%, a figure that would make even top pharma players slightly envious.
Yet, the market hasn’t been too kind lately — the stock is down 32% in the past year. But with zero promoter pledges, an ROE of 15.8%, and almost no debt (₹240 crore against ₹3,587 crore assets), Poly Medicure is clearly more doctor than patient.
And the company isn’t just content making IV sets anymore. It’s on an acquisition rampage — Citieffe, Medistream, PendraCare, Himalayan Water — if it moves, they’ll sterilize it, certify it, and maybe sell it in Europe.
2. Introduction
Poly Medicure Ltd, or as doctors and hospitals know it — that one brand that never stops making more SKUs than Netflix makes new shows. With a product portfolio of over 200+ medical disposables across 12 specialties, the company is the manufacturing equivalent of a Swiss Army knife for hospitals.
Started from a small factory in Faridabad, Polymed has evolved into an export powerhouse, shipping to over 100 countries, while simultaneously maintaining dominance in India’s medical disposables space.
The stock might have underperformed recently, but the business sure hasn’t. The company sold ₹1,229 crore worth of devices in 9MFY25, employs 475 sales professionals, and runs 12 plants with three more under construction — proving that their “make in India, sell everywhere” model is very much alive and injecting.
They’ve also launched 18 new products recently across critical care and cardiology — because when margins tighten, innovation becomes the best painkiller.
So, while some peers play safe in one country or product category, Poly Medicure is operating across five continents, 200+ SKUs, and 334 patents. If diversification were a medical procedure, this company would have already performed it laparoscopically.
3. Business Model – WTF Do They Even Do?
Imagine being the invisible hand that keeps hospitals alive — that’s Poly Medicure. The company manufactures plastic-based medical disposables: IV cannulas, dialysis sets, infusion lines, catheters, syringes, blood bags — basically, everything a hospital needs except the doctor’s ego.
Their three big verticals:
Infusion Therapy (68% of sales) – The star of the show. Tubes, drips, connectors — anything that moves fluid from bottle to body.
Blood Transfusion (10%) – Blood bags, filters, and transfusion sets.
Others (22%) – Dialysis, surgery, wound drainage, and devices that sound like a mix between engineering and Grey’s Anatomy.
Geography-wise, Polymed is evenly split: India (30%), Europe (32%), and Rest of World (38%). It’s like a cricket team that doesn’t rely on one batsman — if Indian hospitals sneeze, European clinics keep them healthy.
They sell through 600 distributors in India and 240 overseas, backed by a large sales force of 475. Each product is CE and MDR certified, meaning even Europe’s bureaucratic regulators can’t find fault (and that’s saying something).
The magic, however, lies in backward integration. The company produces molds, tubes, and even needles in-house — ensuring tight cost control and high quality.
And the kicker? A full-blown CAPEX cycle is on. With ₹400–500 crore planned investment across Palwal, Jaipur, and Haridwar, Polymed isn’t just making more plants; it’s laying pipelines for the next decade’s growth.
4. Financials Overview
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
₹444 Cr
₹420 Cr
₹403 Cr
5.7%
10.2%
EBITDA
₹115 Cr
₹115 Cr
₹106 Cr
0.0%
8.5%
PAT
₹92 Cr
₹87 Cr
₹93 Cr
5.0%
-1.0%
EPS (₹)
9.06
8.63
9.19
5.0%
-1.4%
Witty Commentary: The revenue graph looks like an ECG of a healthy patient — regular, consistent, and slightly improving every quarter. Margins are steady around 26%, and PAT growth is modest but respectable. The company isn’t sprinting; it’s jogging with surgical precision.
5. Valuation Discussion – Fair Value Range
Let’s cut the valuation drama. Polymed trades at a P/E of 53, while the industry median is around 50.
Annualized EPS = ₹9.06 × 4 = ₹36.24
At 45x (conservative) = ₹1,631
At 55x (optimistic) = ₹1,993
Fair Value Range: ₹1,630 – ₹1,990
EV/EBITDA check: EV = ₹19,252 Cr; EBITDA (TTM) = ₹454 Cr → EV/EBITDA = 42.4x. That’s on the premium side but somewhat justified for a global medical device manufacturer.
DCF sanity check: Assume 20% growth next 3 years, terminal 5%, 10% discount rate → roughly ₹1,800–₹2,000 range again.
Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
If you thought this company just makes catheters, think again — it’s been on a global shopping spree that would make even private equity firms jealous.
Nov 2025: Poly Medicure B.V. completed 100% acquisition of Medistream SA and Citieffe Group in Europe —
